Clinical trials: Healthy Humans
Influenza, Human
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults
Healthy adults will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..
- Trial name
- NCT03357263
- Testing
- GC3114, GCFLU Quadrivalent
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza (Healthy Volunteers)
Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older
Primary Objective: To demonstrate the superior relative effectiveness of QIV-HD as compared to QIV-SD among persons 65 years of age and older for the prevention of cardiovascular and/or respiratory hospitalizations.
- Trial name
- NCT04137887
- Testing
- Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD), Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)
- Where
- Finland
- Volunteers
- 33,096 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Migraine
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants
This first in-human (FIH) study of UB-313, an anti-calcitonin gene-related peptide based immunotherapeutic candidate, is designed to assess the safety, tolerability, and immunogenicity of 4 selected UB-313 dose regimens in…
- Trial name
- NCT05477095
- Testing
- UB-313
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
Allergic Conjunctivitis
A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults
The main goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles* of MDI-1228_mesylate Ophthalmic Solution in healthy adult participants.
- Trial name
- NCT05969236
- Testing
- MDI-1228_mesylate Ophthalmic Solution
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Medinno Pharmaceutical Technology Co., Ltd.
COVID-19
SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of APR002 in healthy subjects.
- Trial name
- NCT05268198
- Testing
- APR002
- Where
- Australia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Global Health Drug Discovery Institute
Healthy, Type 1 Diabetes Mellitus
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A
Study Design: Part 1.Randomized, double-blind, placebo-controlled, escalating single-dose design with Healthy volunteers Part 2.Open , sequential, two-period, single dose study with type 1 diabetes Part 3.Open, sequential…
- Conditions
- Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- HM12460A (NCT01724814)
- Testing
- HM12460A
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Obesity Prevention, Obesity and Overweight
Empowering Healthy Lifestyle Personalised Intervention to Prevent and Control Obesity: The HealthyW8 Project
The goal of the HealthyW8 study (an intervention study) is: To assess the usefulness and effects of a digital-based healthy lifestyle recommender system (HRLS) on the prevention of obesity in the following propulations…
- Conditions
- Obesity Prevention, Obesity and Overweight, Obesity and Obesity-related Medical Conditions, Digital Health
- Trial name
- HealthyW8 (NCT07011368)
- Testing
- Intervention Group
- Where
- 13 sites in Bulgaria, Denmark and 6 more
- Volunteers
- 2,720 people, healthy volunteers welcome
- Sponsor
- Fundació d'investigació Sanitària de les Illes Balears
Vasomotor Symptoms Associated With Menopause, Healthy Volunteers
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
The purpose of this study is to evaluate the effects of single and multiple doses of ABCL635 administered by subcutaneous (SC) injection to healthy men and to postmenopausal women with or without any vasomotor symptoms (VMS) or…
- Trial name
- NCT07118891
- Testing
- ABCL635
- Where
- 13 sites in Canada
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- AbCellera Biologics Inc.
Bacterial Infections, Virus Diseases
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
This study will determine whether participants who receive V419 (PR5I) at 2, 4, and 11 to 12 months of age have an acceptable response to the vaccine.
- Trial name
- NCT01480258
- Testing
- PR5I, Rotavirus vaccine, Prevenar 13™
- Volunteers
- 1,315 people, healthy volunteers welcome
- Sponsor
- MCM Vaccines B.V.
Hepatitis C Infection, HIV Infection
A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
This study is aimed at assessing the safety of candidate Hepatitis C vaccines AdCh3NSmut/MVA-NSmut and HIV vaccines ChAdV63.HIVconsv/MVA.HIVconsv when administered separately or in combination to healthy volunteers.
- Trial name
- NCT02362217
- Testing
- AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Imumune Thrombocytopenia(ITP) Human Mass Balance
Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects
To evaluate the absorption, metabolism and excretion of HMPL-523 in healthy male Chinese subjects following multiple oral doses of HMPL-523 tablets followed by a single oral dose of [14C]HMPL-523 suspension
- Trial name
- NCT05781906
- Testing
- HMPL-523, 150 µCi [14C]HMPL-523
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Diphtheria, Tetanus
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
The present trial is a follow-up of AL203 study (NCT00343889). Primary Objectives: To describe the antibody persistence at 15 to 18 months of age and the booster effect of a dose of DTaP-HB-PRP~T or Tritanrix-HepB/Hib™ (given…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00534833
- Testing
- DTaP-HB-PRP~T vaccine, Tritanrix-HepB/Hib™, Oral Polio Vaccine
- Where
- 2 sites in Philippines
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Volunteers, Influenza
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
The study aims to evaluate an egg-based H5N8 influenza vaccine up to 3 dose levels (low, medium, and high dose) given with or without adjuvant to see if the adjuvant improves vaccine effectiveness.
- Trial name
- NCT07779408
- Testing
- Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant
- Where
- 16 sites in United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hypercholesterolemia
A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants
This first-in-human (FIH) study of VXX-401, an anti-PCSK9 peptide-based immunotherapeutic candidate, is designed to assess the safety, tolerability, immunogenicity, and pharmacodynamics (PD) of VXX-401 and to determine an optimal…
- Trial name
- NCT05762276
- Testing
- VXX-401
- Where
- 5 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
Influenza
Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects
Based on pre-clinical trial data and principle of GCP, the objective of phase I clinical trial is to evaluate safety and immunogenicity of Pan-flu vaccine, an inactivated whole virion H5N1 vaccine with aluminium hydroxide…
- Trial name
- NCT00356798
- Testing
- an inactivated whole virion H5N1 vaccine, adjuvanted
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Healthy
Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fed Condition
This is an open label, randomised, balanced, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study.
- Trial name
- NCT01888263
- Testing
- Lamotrigine
- Where
- India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Healthy Volunteers
First Safety Study in Humans of a Single Dose of CPG 52364
Determine the safety and tolerability of the study drug, CPG 52364, when given as liquid or capsule. Another purpose is to determine how the drug enters and leaves the blood stream and body tissues over time.
- Trial name
- NCT00547014
- Testing
- 52364 3 mg, 52364 10 mg, 52364 30 mg
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Pfizer
Smoking
Exploratory THS 2.1 Biomarkers of Exposure Study
The goal of this exploratory study is to evaluate the effect of a candidate modified risk tobacco product (MRTP), THS 2.1, on selected biomarkers of exposure to harmful and potentially harmful smoke constituents (HPHCs), compared…
- Trial name
- ZRHX-EX-01 (NCT01780714)
- Testing
- Conventional cigarettes (CC), THS 2.1
- Where
- Poland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Human NiV Infection
Community Intervention to Prevent Nipah Spillover
Several human Nipah virus (NiV) outbreaks have occurred in Bangladesh since 2001with 71% case fatality. Outbreak investigations have repeatedly identified drinking fresh date palm sap as a risk factor for NiV transmission.
- Trial name
- NCT01811784
- Testing
- Ask people not to drink raw sap, Ask people not to drink sap or drink sap from skirt protected trees, No Intervention
- Where
- 4 sites in Bangladesh
- Volunteers
- 7,782 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Healthy
First-in-Human Single and Multiple Dose of GLPG2222
The purpose of this First-in-Human study is to evaluate the safety and tolerability after single ascending oral doses of GLPG2222 given to healthy subjects, compared to placebo (Part 1).
- Trial name
- NCT02662452
- Testing
- GLPG2222 single dose, GLPG2222 multiple doses
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.